Vertex Pharmaceuticals (VRTX) Stock Forecast, Price Target & Predictions
VRTX Stock Forecast
Vertex Pharmaceuticals stock forecast is as follows: an average price target of $403.92 (represents a -10.48% downside from VRTX’s last price of $451.23) and a rating consensus of 'Buy', based on 21 wall street analysts offering a 1-year stock forecast.
VRTX Price Target
The average price target for Vertex Pharmaceuticals (VRTX) is $403.92 based on 1-year price targets from 21 Wall Street analysts in the past 3 months, with a price target range of $600.00 to $240.00. This represents a potential -10.48% downside from VRTX's last price of $451.23.
VRTX Analyst Ratings
According to 21 Wall Street analysts, Vertex Pharmaceuticals's rating consensus is 'Buy'. The analyst rating breakdown for VRTX stock is 0 'Strong Buy' (0.00%), 12 'Buy' (57.14%), 8 'Hold' (38.10%), 1 'Sell' (4.76%), and 0 'Strong Sell' (0.00%).
Vertex Pharmaceuticals Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Nov 05, 2024 | Hartaj Singh | Oppenheimer | $540.00 | $499.10 | 8.19% | 19.67% |
| Nov 05, 2024 | Brian Abrahams | RBC Capital | $451.00 | $499.88 | -9.78% | -0.05% |
| Oct 22, 2024 | Whitney Ijem | Canaccord Genuity | $361.00 | $478.09 | -24.49% | -20.00% |
| Oct 21, 2024 | Evan David Seigerman | BMO Capital | $566.00 | $485.74 | 16.52% | 25.43% |
| Oct 21, 2024 | Salveen Richter | Goldman Sachs | $598.00 | $483.00 | 23.81% | 32.53% |
| Oct 14, 2024 | Geoff Meacham | Bank of America Securities | $541.00 | $482.12 | 12.21% | 19.89% |
| Oct 09, 2024 | Brian Abrahams | RBC Capital | $437.00 | $458.94 | -4.78% | -3.15% |
| Aug 05, 2024 | Joon Lee | Truist Financial | $550.00 | $494.46 | 11.23% | 21.89% |
| Aug 05, 2024 | Hartaj Singh | Oppenheimer | $550.00 | $477.86 | 15.10% | 21.89% |
| Aug 05, 2024 | Andy Chen | Wolfe Research | $576.00 | $476.91 | 20.78% | 27.65% |
The latest Vertex Pharmaceuticals stock forecast, released on Nov 05, 2024 by Hartaj Singh from Oppenheimer, set a price target of $540.00, which represents a 8.19% increase from the stock price at the time of the forecast ($499.10), and a 19.67% increase from VRTX last price ($451.23).
Vertex Pharmaceuticals Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | 5 | 7 | 18 |
| Avg Price Target | $503.20 | $499.14 | $501.17 |
| Last Closing Price | $451.23 | $451.23 | $451.23 |
| Upside/Downside | 11.52% | 10.62% | 11.07% |
In the current month, the average price target of Vertex Pharmaceuticals stock is $503.20, according to 5 Wall Street analysts offering twelve months forecast. The average price target represents a 11.52% increase as opposed to Vertex Pharmaceuticals's last price of $451.23. This month's average price target is up 0.81% compared to last quarter, and up 0.41% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Nov 13, 2024 | Citigroup | - | Buy | Initialise |
| Oct 22, 2024 | Canaccord Genuity | Sell | Sell | Hold |
| Oct 21, 2024 | BMO Capital | Outperform | Outperform | Hold |
| Oct 21, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Oct 21, 2024 | Goldman Sachs | Buy | Buy | Hold |
| Oct 17, 2024 | UBS | Sector Perform | Sector Perform | Hold |
| Oct 17, 2024 | UBS | Buy | Buy | Hold |
| Oct 16, 2024 | Scotiabank | - | Sector Perform | Initialise |
| Oct 01, 2024 | RBC Capital | Sector Perform | Sector Perform | Hold |
| Oct 01, 2024 | Piper Sandler | Underperform | Underperform | Hold |
Vertex Pharmaceuticals's last stock rating was published by Citigroup on Nov 13, 2024. The company Initialise its VRTX rating from "null" to "Buy".
Vertex Pharmaceuticals Financial Forecast
Vertex Pharmaceuticals Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | $2.48B | $2.49B | $2.37B | $2.30B | $2.33B | $2.20B | $2.10B | $2.07B | $1.98B | $1.79B | $1.72B | $1.63B | $1.54B | $1.52B | $1.52B | $1.41B | $949.83M | $941.29M | $858.43M | $640.80M | $714.72M |
| Avg Forecast | $3.16B | $2.93B | $2.84B | $2.80B | $2.78B | $2.69B | $2.66B | $2.58B | $2.51B | $2.50B | $2.42B | $2.34B | $2.30B | $2.23B | $2.13B | $2.07B | $2.00B | $1.86B | $1.72B | $1.66B | $1.59B | $1.49B | $1.39B | $1.30B | $1.01B | $950.95M | $886.16M | $851.35M | $531.19M | $679.84M |
| High Forecast | $3.27B | $3.04B | $2.94B | $2.81B | $2.88B | $2.69B | $2.66B | $2.58B | $2.56B | $2.58B | $2.51B | $2.42B | $2.39B | $2.23B | $2.13B | $2.07B | $2.00B | $1.86B | $1.72B | $1.66B | $1.59B | $1.49B | $1.39B | $1.30B | $1.01B | $950.95M | $886.16M | $851.35M | $637.43M | $815.80M |
| Low Forecast | $3.09B | $2.87B | $2.77B | $2.79B | $2.72B | $2.68B | $2.66B | $2.58B | $2.44B | $2.42B | $2.36B | $2.28B | $2.25B | $2.23B | $2.13B | $2.07B | $2.00B | $1.86B | $1.72B | $1.66B | $1.59B | $1.49B | $1.39B | $1.30B | $1.01B | $950.95M | $886.16M | $851.35M | $424.95M | $543.87M |
| # Analysts | 4 | 4 | 4 | 6 | 20 | 10 | 6 | 6 | 12 | 25 | 12 | 12 | 11 | 11 | 11 | 11 | 12 | 12 | 12 | 12 | 12 | 9 | 9 | 9 | 5 | 5 | 5 | 5 | 12 | 11 |
| Surprise % | - | - | - | - | - | - | - | - | - | 0.99% | 1.03% | 1.02% | 1.00% | 1.05% | 1.03% | 1.01% | 1.03% | 1.07% | 1.04% | 1.04% | 1.02% | 1.04% | 1.09% | 1.17% | 1.39% | 1.00% | 1.06% | 1.01% | 1.21% | 1.05% |
Vertex Pharmaceuticals's average Quarter revenue forecast for Dec 23 based on 12 analysts is $2.51B, with a low forecast of $2.44B, and a high forecast of $2.56B. VRTX's average Quarter revenue forecast represents a 1.18% increase compared to the company's last Quarter revenue of $2.48B (Sep 23).
Vertex Pharmaceuticals EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 4 | 4 | 4 | 6 | 20 | 10 | 6 | 6 | 12 | 25 | 12 | 12 | 11 | 11 | 11 | 11 | 12 | 12 | 12 | 12 | 12 | 9 | 9 | 9 | 5 | 5 | 5 | 5 | 12 | 11 |
| EBITDA | - | - | - | - | - | - | - | - | - | $1.04B | $1.03B | $1.25B | $1.11B | $1.22B | $1.05B | $962.20M | $919.88M | $1.13B | $2.46M | $865.47M | $934.27M | $786.37M | $865.34M | $698.49M | $717.46M | $111.06M | $369.67M | $362.17M | $225.04M | $283.36M |
| Avg Forecast | $1.43B | $1.32B | $1.28B | $1.26B | $1.25B | $1.21B | $1.20B | $1.21B | $1.13B | $1.13B | $1.09B | $1.10B | $990.40M | $944.75M | $903.19M | $996.96M | $848.40M | $786.34M | $728.04M | $772.17M | $674.89M | $629.50M | $589.97M | $430.42M | $429.87M | $402.87M | $375.42M | $298.70M | $178.61M | $268.82M |
| High Forecast | $1.48B | $1.37B | $1.32B | $1.27B | $1.30B | $1.21B | $1.20B | $1.45B | $1.15B | $1.16B | $1.13B | $1.32B | $1.19B | $944.75M | $903.19M | $1.20B | $848.40M | $786.34M | $728.04M | $926.60M | $674.89M | $629.50M | $589.97M | $516.51M | $429.87M | $402.87M | $375.42M | $358.44M | $214.33M | $322.59M |
| Low Forecast | $1.39B | $1.29B | $1.25B | $1.26B | $1.23B | $1.21B | $1.20B | $965.05M | $1.10B | $1.09B | $1.06B | $877.32M | $792.32M | $944.75M | $903.19M | $797.56M | $848.40M | $786.34M | $728.04M | $617.73M | $674.89M | $629.50M | $589.97M | $344.34M | $429.87M | $402.87M | $375.42M | $238.96M | $142.89M | $215.06M |
| Surprise % | - | - | - | - | - | - | - | - | - | 0.92% | 0.94% | 1.14% | 1.12% | 1.29% | 1.16% | 0.97% | 1.08% | 1.44% | 0.00% | 1.12% | 1.38% | 1.25% | 1.47% | 1.62% | 1.67% | 0.28% | 0.98% | 1.21% | 1.26% | 1.05% |
12 analysts predict VRTX's average Quarter EBITDA for Dec 23 to be $1.13B, with a high of $1.15B and a low of $1.10B. This is 9.05% upper than Vertex Pharmaceuticals's previous annual EBITDA (Sep 23) of $1.04B.
Vertex Pharmaceuticals Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 4 | 4 | 4 | 6 | 20 | 10 | 6 | 6 | 12 | 25 | 12 | 12 | 11 | 11 | 11 | 11 | 12 | 12 | 12 | 12 | 12 | 9 | 9 | 9 | 5 | 5 | 5 | 5 | 12 | 11 |
| Net Income | - | - | - | - | - | - | - | - | - | $1.04B | $915.70M | $699.80M | $818.90M | $930.50M | $810.50M | $762.10M | $770.11M | $851.93M | $66.92M | $653.14M | $604.19M | $667.43M | $837.27M | $602.75M | $583.23M | $57.52M | $267.43M | $268.63M | $210.26M | $247.76M |
| Avg Forecast | $1.34B | $1.26B | $1.22B | $1.16B | $1.06B | $1.06B | $-3.03B | $914.21M | $1.06B | $1.03B | $1.01B | $831.10M | $829.15M | $932.39M | $896.54M | $755.55M | $848.30M | $797.46M | $653.32M | $582.73M | $663.24M | $605.26M | $537.21M | $371.43M | $313.26M | $297.52M | $275.65M | $221.55M | $166.88M | $235.05M |
| High Forecast | $1.40B | $1.32B | $1.28B | $1.39B | $1.29B | $1.07B | $-2.94B | $1.10B | $1.15B | $1.13B | $1.05B | $997.32M | $994.98M | $932.39M | $896.54M | $906.66M | $848.30M | $797.46M | $653.32M | $699.27M | $663.24M | $605.26M | $537.21M | $445.71M | $313.26M | $297.52M | $275.65M | $265.86M | $200.25M | $282.06M |
| Low Forecast | $1.30B | $1.22B | $1.18B | $1.02B | $933.98M | $1.06B | $-3.17B | $731.37M | $960.03M | $861.61M | $976.09M | $664.88M | $663.32M | $932.39M | $896.54M | $604.44M | $848.30M | $797.46M | $653.32M | $466.18M | $663.24M | $605.26M | $537.21M | $297.14M | $313.26M | $297.52M | $275.65M | $177.24M | $133.50M | $188.04M |
| Surprise % | - | - | - | - | - | - | - | - | - | 1.01% | 0.91% | 0.84% | 0.99% | 1.00% | 0.90% | 1.01% | 0.91% | 1.07% | 0.10% | 1.12% | 0.91% | 1.10% | 1.56% | 1.62% | 1.86% | 0.19% | 0.97% | 1.21% | 1.26% | 1.05% |
Vertex Pharmaceuticals's average Quarter net income forecast for Dec 23 is $1.06B, with a range of $960.03M to $1.15B. VRTX's average Quarter net income forecast represents a 2.53% increase compared to the company's last Quarter net income of $1.04B (Sep 23).
Vertex Pharmaceuticals SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 4 | 4 | 4 | 6 | 20 | 10 | 6 | 6 | 12 | 25 | 12 | 12 | 11 | 11 | 11 | 11 | 12 | 12 | 12 | 12 | 12 | 9 | 9 | 9 | 5 | 5 | 5 | 5 | 12 | 11 |
| SG&A | - | - | - | - | - | - | - | - | - | $263.80M | $262.60M | $241.10M | $267.40M | $246.80M | $215.30M | $215.20M | $255.16M | $198.19M | $194.67M | $192.08M | $211.84M | $184.55M | $191.80M | $182.26M | $195.28M | $159.67M | $156.50M | $147.04M | $129.81M | $113.33M |
| Avg Forecast | $388.57M | $360.51M | $348.42M | $343.67M | $341.65M | $329.88M | $327.20M | $258.15M | $308.67M | $307.28M | $297.35M | $234.69M | $274.73M | $274.09M | $262.03M | $213.35M | $246.14M | $228.13M | $211.22M | $171.37M | $195.80M | $182.63M | $171.16M | $112.31M | $124.72M | $116.88M | $108.92M | $121.27M | $103.02M | $107.51M |
| High Forecast | $402.28M | $373.24M | $360.72M | $344.96M | $353.99M | $330.11M | $327.20M | $309.78M | $314.85M | $316.72M | $307.84M | $281.62M | $329.67M | $274.09M | $262.03M | $256.02M | $246.14M | $228.13M | $211.22M | $205.64M | $195.80M | $182.63M | $171.16M | $134.77M | $124.72M | $116.88M | $108.92M | $145.53M | $123.63M | $129.02M |
| Low Forecast | $379.33M | $351.94M | $340.14M | $342.39M | $334.25M | $329.65M | $327.20M | $206.52M | $300.03M | $297.66M | $290.28M | $187.75M | $219.78M | $274.09M | $262.03M | $170.68M | $246.14M | $228.13M | $211.22M | $137.10M | $195.80M | $182.63M | $171.16M | $89.85M | $124.72M | $116.88M | $108.92M | $97.02M | $82.42M | $86.01M |
| Surprise % | - | - | - | - | - | - | - | - | - | 0.86% | 0.88% | 1.03% | 0.97% | 0.90% | 0.82% | 1.01% | 1.04% | 0.87% | 0.92% | 1.12% | 1.08% | 1.01% | 1.12% | 1.62% | 1.57% | 1.37% | 1.44% | 1.21% | 1.26% | 1.05% |
Vertex Pharmaceuticals's average Quarter SG&A projection for Dec 23 is $308.67M, based on 12 Wall Street analysts, with a range of $300.03M to $314.85M. The forecast indicates a 17.01% rise compared to VRTX last annual SG&A of $263.80M (Sep 23).
Vertex Pharmaceuticals EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 4 | 4 | 4 | 6 | 20 | 10 | 6 | 6 | 12 | 25 | 12 | 12 | 11 | 11 | 11 | 11 | 12 | 12 | 12 | 12 | 12 | 9 | 9 | 9 | 5 | 5 | 5 | 5 | 12 | 11 |
| EPS | - | - | - | - | - | - | - | - | - | $4.01 | $3.55 | $2.72 | $3.19 | $3.63 | $3.17 | $2.99 | $3.02 | $3.30 | $0.26 | $2.52 | $2.32 | $2.56 | $3.22 | $2.32 | $2.26 | $0.22 | $1.04 | $1.05 | $0.83 | $1.01 |
| Avg Forecast | $5.13 | $4.84 | $4.67 | $4.46 | $4.07 | $4.08 | $-11.63 | $4.07 | $4.07 | $3.93 | $3.86 | $3.01 | $3.53 | $3.61 | $3.47 | $3.57 | $3.29 | $3.09 | $2.53 | $2.70 | $2.57 | $2.35 | $2.08 | $1.87 | $1.21 | $1.15 | $1.07 | $1.01 | $0.50 | $0.37 |
| High Forecast | $5.36 | $5.06 | $4.89 | $5.33 | $4.93 | $4.10 | $-11.27 | $4.07 | $4.42 | $4.34 | $4.04 | $3.15 | $3.69 | $3.61 | $3.47 | $3.57 | $3.29 | $3.09 | $2.53 | $2.70 | $2.57 | $2.35 | $2.08 | $1.87 | $1.21 | $1.15 | $1.07 | $1.01 | $0.60 | $0.44 |
| Low Forecast | $4.97 | $4.69 | $4.53 | $3.90 | $3.58 | $4.06 | $-12.16 | $4.07 | $3.68 | $3.30 | $3.74 | $2.92 | $3.42 | $3.61 | $3.47 | $3.57 | $3.29 | $3.09 | $2.53 | $2.70 | $2.57 | $2.35 | $2.08 | $1.87 | $1.21 | $1.15 | $1.07 | $1.01 | $0.40 | $0.30 |
| Surprise % | - | - | - | - | - | - | - | - | - | 1.02% | 0.92% | 0.90% | 0.90% | 1.00% | 0.91% | 0.84% | 0.92% | 1.07% | 0.10% | 0.93% | 0.90% | 1.09% | 1.55% | 1.24% | 1.86% | 0.19% | 0.97% | 1.04% | 1.66% | 2.73% |
According to 12 Wall Street analysts, Vertex Pharmaceuticals's projected average Quarter EPS for Dec 23 is $4.07, with a low estimate of $3.68 and a high estimate of $4.42. This represents a 1.42% increase compared to VRTX previous annual EPS of $4.01 (Sep 23).
Vertex Pharmaceuticals Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| NTLA | Intellia Therapeutics | $13.12 | $115.90 | 783.38% | Buy |
| EDIT | Editas Medicine | $2.41 | $12.85 | 433.20% | Buy |
| VERV | Verve Therapeutics | $4.55 | $19.00 | 317.58% | Buy |
| MRNA | Moderna | $36.94 | $140.57 | 280.54% | Hold |
| BEAM | Beam Therapeutics | $24.49 | $58.50 | 138.87% | Buy |
| CRSP | CRISPR Therapeutics | $47.26 | $101.46 | 114.68% | Buy |
| VKTX | Viking Therapeutics | $51.53 | $102.40 | 98.72% | Buy |
| BMRN | BioMarin Pharmaceutical | $62.56 | $101.70 | 62.56% | Buy |
| BNTX | BioNTech SE | $102.14 | $165.07 | 61.61% | Buy |
| CRBU | Caribou Biosciences | $1.96 | $3.00 | 53.06% | Buy |
| SRPT | Sarepta Therapeutics | $110.86 | $169.06 | 52.50% | Buy |
| REGN | Regeneron Pharmaceuticals | $743.35 | $995.63 | 33.94% | Buy |
| DNA | Ginkgo Bioworks | $6.36 | $7.34 | 15.41% | Buy |
| PTCT | PTC Therapeutics | $41.96 | $46.50 | 10.82% | Hold |
| KRYS | Krystal Biotech | $178.10 | $191.00 | 7.24% | Buy |
| ALNY | Alnylam Pharmaceuticals | $248.79 | $254.21 | 2.18% | Buy |
| MDGL | Madrigal Pharmaceuticals | $317.09 | $315.75 | -0.42% | Buy |
| VRTX | Vertex Pharmaceuticals | $451.23 | $403.92 | -10.48% | Buy |